Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

Comparative diagnostic accuracy of 18F-FDG PET/CT for breast cancer recurrence.

Piva R, Ticconi F, Ceriani V, Scalorbi F, Fiz F, Capitanio S, Bauckneht M, Cittadini G, Sambuceti G, Morbelli S.

Breast Cancer (Dove Med Press). 2017 Jul 4;9:461-471. doi: 10.2147/BCTT.S111098. eCollection 2017. Review.

2.

Defining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future Perspectives.

Subbiah V, Chuang HH, Gambhire D, Kairemo K.

Diagnostics (Basel). 2017 Feb 15;7(1). pii: E10. doi: 10.3390/diagnostics7010010.

3.

Radiology Consultation in the Era of Precision Oncology: A Review of Consultation Models and Services in the Tertiary Setting.

DiPiro PJ, Krajewski KM, Giardino AA, Braschi-Amirfarzan M, Ramaiya NH.

Korean J Radiol. 2017 Jan-Feb;18(1):18-27. doi: 10.3348/kjr.2017.18.1.18. Epub 2017 Jan 5. Review.

4.
5.

Bone Scan Index predicts skeletal-related events in patients with metastatic breast cancer.

Idota A, Sawaki M, Yoshimura A, Hattori M, Inaba Y, Oze I, Kikumori T, Kodera Y, Iwata H.

Springerplus. 2016 Jul 16;5(1):1095. doi: 10.1186/s40064-016-2741-0. eCollection 2016.

6.

Metastatic mimics on bone scan: "All that glitters is not metastatic".

Agrawal A, Purandare N, Shah S, Rangarajan V.

Indian J Nucl Med. 2016 Jul-Sep;31(3):185-90. doi: 10.4103/0972-3919.183605.

7.

Immunolocalization of MMP9 and MMP2 in osteolytic metastasis originating from MDA-MB-231 human breast cancer cells.

Liu B, Cui J, Sun J, Li J, Han X, Guo J, Yi M, Amizuka N, Xu X, Li M.

Mol Med Rep. 2016 Aug;14(2):1099-106. doi: 10.3892/mmr.2016.5374. Epub 2016 Jun 7.

8.

Osteoblastic lesion screening with an advanced post-processing package enabling in-plane rib reading in CT-images.

Seuss H, Dankerl P, Cavallaro A, Uder M, Hammon M.

BMC Med Imaging. 2016 May 20;16(1):39. doi: 10.1186/s12880-016-0141-0.

9.

Differential effect of zoledronic acid on normal trabecular and cortical bone density in oncologic patients with bone metastases.

Quattrocchi CC, Dell'Aia P, Errante Y, Occhicone F, Longo D, Virzì V, Tonini G, Napoli N, Santini D, Beomonte Zobel B.

J Bone Oncol. 2012 Mar 23;1(1):24-9. doi: 10.1016/j.jbo.2012.02.001. eCollection 2012 Jun.

10.

Galectin-3 Cleavage Alters Bone Remodeling: Different Outcomes in Breast and Prostate Cancer Skeletal Metastasis.

Nakajima K, Kho DH, Yanagawa T, Harazono Y, Hogan V, Chen W, Ali-Fehmi R, Mehra R, Raz A.

Cancer Res. 2016 Mar 15;76(6):1391-402. doi: 10.1158/0008-5472.CAN-15-1793. Epub 2016 Feb 2.

12.

Systemic treatment in breast cancer: a primer for radiologists.

Michaels AY, Keraliya AR, Tirumani SH, Shinagare AB, Ramaiya NH.

Insights Imaging. 2016 Feb;7(1):131-44. doi: 10.1007/s13244-015-0447-4. Epub 2015 Nov 13.

13.

Use of Animal Models in Understanding Cancer-induced Bone Pain.

Slosky LM, Largent-Milnes TM, Vanderah TW.

Cancer Growth Metastasis. 2015 Aug 23;8(Suppl 1):47-62. doi: 10.4137/CGM.S21215. eCollection 2015. Review.

14.

Comparison of 18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma.

Hogan MP, Goldman DA, Dashevsky B, Riedl CC, Gönen M, Osborne JR, Jochelson M, Hudis C, Morrow M, Ulaner GA.

J Nucl Med. 2015 Nov;56(11):1674-80. doi: 10.2967/jnumed.115.161455. Epub 2015 Aug 20.

15.

Pilot Prospective Evaluation of (18)F-Alfatide II for Detection of Skeletal Metastases.

Mi B, Yu C, Pan D, Yang M, Wan W, Niu G, Chen X.

Theranostics. 2015 Jul 12;5(10):1115-21. doi: 10.7150/thno.12938. eCollection 2015.

16.

Positron emission tomography of tumour [(18)F]fluoroestradiol uptake in patients with acquired hormone-resistant metastatic breast cancer prior to oestradiol therapy.

van Kruchten M, Glaudemans AW, de Vries EF, Schröder CP, de Vries EG, Hospers GA.

Eur J Nucl Med Mol Imaging. 2015 Oct;42(11):1674-81. doi: 10.1007/s00259-015-3107-5. Epub 2015 Jun 20.

17.

Evaluation of radiographic and metabolic changes in bone metastases in response to systemic therapy with (18)FDG-PET/CT.

Gunalp B, Oner AO, Ince S, Alagoz E, Ayan A, Arslan N.

Radiol Oncol. 2015 Mar 25;49(2):115-20. doi: 10.1515/raon-2015-0012. eCollection 2015 Jun.

18.

Differentiation of metastatic vs degenerative joint disease using semi-quantitative analysis with (18)F-NaF PET/CT in castrate resistant prostate cancer patients.

Muzahir S, Jeraj R, Liu G, Hall LT, Rio AM, Perk T, Jaskowiak C, Perlman SB.

Am J Nucl Med Mol Imaging. 2015 Jan 15;5(2):162-8. eCollection 2015.

19.

Appearance of untreated bone metastases from breast cancer on FDG PET/CT: importance of histologic subtype.

Dashevsky BZ, Goldman DA, Parsons M, Gönen M, Corben AD, Jochelson MS, Hudis CA, Morrow M, Ulaner GA.

Eur J Nucl Med Mol Imaging. 2015 Oct;42(11):1666-73. doi: 10.1007/s00259-015-3080-z. Epub 2015 May 14.

20.

Supplemental Content

Support Center